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Background: Although many Asian type 2 diabetic patients have been considered to be not obese and have low
capacity of insulin secretion, the proportion of obese patients with visceral fat accumulation has increased in recent
years. We found previously considerable number of Japanese non-obese subjects (body mass index (BMI) < 25 kg/m2)
with visceral fat accumulation and multiple cardiovascular risk factors. The aim of the study was to investigate the
difference in clinical features of type 2 diabetic patients with and without visceral fat accumulation, focusing on
vascular complications and changes in BMI.
Methods: We enrolled 88 Japanese hospitalized type 2 diabetic patients. Abdominal obesity represented waist
circumference (WC) of ≥85 cm for males and ≥90 cm for females (corresponding to visceral fat area of 100 cm2).
Subjects were divided into two groups; with or without abdominal obesity.
Results: Hypertension, dyslipidemia and cardiovascular diseases were significantly more in the patients with abdominal
obesity. The prevalence of cardiovascular disease in the non-obese patients (BMI < 25 kg/m2) with abdominal obesity
were similar in obese patients (BMI ≥25 kg/m2). The mean BMI of the patients with abdominal obesity was < 25 kg/m2
at 20 years of age, but reached maximum to more than 30 kg/m2 in the course. Furthermore, substantial portion of the
type 2 diabetic patients (52% in males and 43% in females) were not obese at 20 year-old (BMI < 25 kg/m2), but
developed abdominal obesity by the time of admission.
Conclusion: These results emphasize the need to control multiple risk factors and prevent atherosclerotic disease in
patients with abdominal obesity. The significant weight gain after 20 years of age in patients with abdominal obesity
stresses the importance of lifestyle modification in younger generation, to prevent potential development of type 2
diabetes and future atherosclerotic cardiovascular disease.
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The prevalence of type 2 diabetes and obesity has in-
creased worldwide, especially in Asia, in association with
visceral fat accumulation [1-4]. Previous studies indicated
that many Asian diabetic patients are not obese and have
low capacity of insulin secretion [5-7]. However, recent
evidence from some studies suggested that obesity and
visceral fat accumulation were closely related to the inci-
dence of type 2 diabetes [8-10]. Our group reported re-
cently that obese type 2 diabetic patients secrete high
insulin levels after oral glucose loading than non-obese
patients [11].
Body mass index (BMI) is widely used to assess adi-
posity. Asians and Japanese could be easily affected with
type 2 diabetes mellitus, including those with relatively
low BMI compared to Caucasians [7]. Furthermore, even
within the non-obese (BMI < 25 kg/m2), increase in BMI
was reported to escalate the risk of type 2 diabetes
mellitus in Japanese population [8]. We reported previ-
ously the identification of a considerable proportion of
Japanese subjects with visceral fat accumulation (visceral
fat area, VFA ≥100 cm2) whose BMI was less than 25 kg/
m2, and that subjects with visceral fat accumulation
without overall obesity (VFA ≥100 cm2 plus BMI < 25 kg/
m2) had multiple cardiovascular risk factors [12].
There is ample evidence for the role of visceral fat ac-
cumulation in the development of multiple metabolic
disorders including glucose intolerance, dyslipidemia,
elevated blood pressure, and atherosclerotic cardiovas-
cular diseases [13-20]. Collectively, these data suggest
that assessment of visceral fat accumulation is useful
for evaluation of high-risk group for atherosclerotic
cardiovascular diseases, and also type 2 diabetes. How-
ever, to date, it has not been well characterized about
the state of body weight in younger age of the current
type 2 diabetic patients with visceral fat accumulation.
Our group has reported previously that the mean vis-
ceral fat area increased with age after 20’s in general
population [21]. It may be important to know whether
current type 2 patients with visceral fat accumulation
has been obese or not at 20 years of age, to prevent
visceral fat accumulation.
Clinically, waist circumference (WC) is used as a tool
for estimation of VFA. In Japanese population, VFA of
100 cm2 has been demonstrated to correspond approxi-
mately to WC of 85 cm in male and 90 cm in female
[21,22]. Therefore, in Japanese guidelines for the meta-
bolic syndrome, WC is used as an index of visceral fat
accumulation for practical convenience [23].
The aim of this study is to investigate the difference in
clinical features of type 2 diabetic patients with or with-
out abdominal obesity (WC ≥85 cm in males, ≥90 cm in
females), with a special focus on vascular complications
and changes in BMI.Methods
Subjects
The study subjects were 88 Japanese type 2 diabetic
patients who had been hospitalized because of poor
glycemic control and/or the staging of complications at
three institutions: Department of Endocrinology and
Metabolism in Osaka University Hospital during the
period from January 2010 to December 2010 (consecu-
tive 54 patients were enrolled), Ikeda Municipal Hospital
during the period from July 2011 to December 2011
(consecutive 16 patients were enrolled), Suita Municipal
Hospital during the period from August 2011 to March
2012 (consecutive 18 patients were enrolled). The
Medical Ethics Committee of Osaka University approved
the study. Each participant gave a written informed
consent.
Type 2 diabetes was defined according to the World
Health Organization (WHO) National diabetic group
criteria of 2006 and/or treatment of diabetes. The fol-
lowing patients were excluded, (1) patients in whom
WC was not measured, (2) patients who were younger
than 40 years or older than 64 years on admission, (3)
patients who were diagnosed with type 1 diabetes
mellitus, (4) patients positive for anti-GAD antibody, (5)
patients who did not attend the diabetes education
course due to severity of their illness.
Clinical examination
Body weight at 20 years of age and maximum body
weight were retrieved through medical interview. The
duration of diabetes and the number of hospitalizations
were determined from the medical interview and med-
ical records. Second-degree family history of diabetes
was obtained from every patient. Height (cm), weight
(kg) and WC at umbilical level (cm) were measured in
the standing position on admission. Diabetic retinopathy
was assessed by an ophthalmologist. The stages of dia-
betic nephropathy were classified as normoalbuminuria
[urinary albumin-creatinine ratio (UACR): < 30 mg/g
creatinine], microalbuminuria (UACR 30–299 mg/g cre-
atinine) and overt proteinuria (UACR: ≥300 mg/g
creatinine). Venous blood samples were collected after
overnight fasting for measurement of high-density lipo-
protein cholesterol, low-density lipoprotein cholesterol,
triglyceride, insulin, C-peptide, creatinine and HbA1c
(Japan Diabetes Society, JDS). The value for HbA1c (%)
was estimated as National Glycohemoglobin Standar-
dization Program (NGSP) equivalent value (%), calcu-
lated by the formula HbA1c (%) =1.02 ×HbA1c(JDS)+0.25
[24]. The homeostasis model assessment of insulin
resistance (HOMA-IR = fasting plasma glucose (mg/
dL) × fasting immunoreactive insulin (μU/mL) / 405)
was evaluated after achieving fair glycemic control
(fasting plasma glucose <140 mg/dL [25]), but patients
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intima-media thickness (IMT) of the carotid artery
was measured in supine position by echography.
Maximum carotid IMT was measured on both the
right and left sides in the observation-possible areas
of the common carotid artery, bulbus, and internal
carotid artery, but not the external carotid artery.
Definition of abdominal obesity, hypertension,
dyslipidemia and cardiovascular disease
Abdominal obesity was assessed WC of ≥85 cm for
males and ≥90 cm for females [21,22]. Hypertension was
defined as systolic blood pressure of ≥140 mmHg and/or
diastolic blood pressure of ≥90 mmHg. Dyslipidemia was
defined as low-density lipoprotein cholesterol concen-
tration of >140 mg/dL and/or triglyceride concentration
of >150 mg/dL and/or high-density lipoprotein cholesterol
concentration of < 40 mg/dL. If patients received anti-
hypertensive and /or anti-lipidemic medications, they
were considered positive for hypertension and /or
dyslipidemia. Cardiovascular disease was defined as cor-
onary artery disease (CAD) and/or cerebrovascular disease
and/or peripheral arterial disease (PAD). CAD was defined
as significant coronary stenosis(es) by coronary angiog-
raphy or computed tomography, and/or positive ischemia
by stress myocardial scintigraphy. Cerebrovascular disease
was defined as history of stroke by a medical interview
and/or old cerebral infarction by magnetic resonance
imaging (MRI). PAD was defined as ankle-brachial index
(ABI) ≤ 0.9 or performance of a revascularization proced-
ure or amputation of lower extremity because of PAD
[26,27].
Statistical analysis
All values were expressed as mean ± SD. In all cases,
probability (P) values of < 0.05 were considered statisti-
cally significant. We performed unpaired t-test to deter-
mine the difference in various parameters between two
groups (Table 1). Frequencies were compared between
two groups by the Fisher’s exact test (Table 1, Figures 1).
Changes in BMI in the same group were analyzed by
paired t-test (Figure 2). Cochran-Armitage trend test was
used to analyze the relationship between two groups of
diabetic retinopathy and diabetic nephropathy (Table 1).
All analyses were conducted by using the JMP version
9.0.2 for Windows (SAS Institute, Cary, NC).
Results
Characteristics of participants
We enrolled 88 Japanese patients in this study (51 men
and 37 women; age, 55.1±7.1 years [mean ± SD]; range,
40–64 years, BMI 26.2±5.5 kg/m2, WC; males 91.4±9.8 cm,
females 91.8±13.4 cm). We divided the patients into two
groups by WC. Abdominal obesity was defined asWC ≥85 cm in males, WC ≥90 cm in females [19].
Patients with smaller WC formed the abdominal obes-
ity (−) group. Table 1 summarizes the profiles of the
60 patients (68%) of the abdominal obesity (+) group
and 28 patients (32%) of the abdominal obesity (−)
group. There were no significant differences in age,
duration of diabetes, family history of diabetes, HbA1c,
fasting plasma glucose and maximum carotid IMT
between the two groups. Furthermore, there were no sig-
nificant differences in the percentage of patients with
microangiopathies (diabetic retinopathy and diabetic
nephropathy) between the two groups. On the other hand,
BMI, fasting insulin, fasting C-peptide and HOMA-IR of
the abdominal obesity (+) group were higher than those of
the abdominal obesity (−) group.
Clinical features of type 2 diabetic patients with
abdominal obesity
Hypertension and dyslipidemia were significantly more
common in the abdominal obesity (+) group compared
with the abdominal obesity (−) group (68% vs 29% and
79% vs 57%, respectively, Figure 1A). Prevalence of
cardiovascular diseases was higher in the abdominal
obesity (+) group than the abdominal obesity (−) group
(22% vs 4%, respectively, p < 0.05). Cardiovascular
diseases in detail as follows; CAD 8cases (7 cases in
abdominal obesity (+) group and 1cases in abdominal
obesity (−) group; cerebrovascular disease 4 cases (ab-
dominal obesity (+) group); and PAD 4 cases (abdominal
obesity (+) group). Two patients with abdominal obesity
suffered from two cardiovascular diseases, respectively
(CAD + PAD and cerebrovascular disease + PAD).
Next, we investigated the relationship between preva-
lence of cardiovascular disease and body fat distribution.
Subjects were divided according to their BMI and WC
(Figure 1B). Among 88 patients, 50 patients (57%) were
obese (BMI ≥25 kg/m2) with abdominal obesity. Among
the non-obese (BMI < 25 kg/m2) patients, abdominal
obesity was common (10/38: 26%) and the prevalence of
cardiovascular disease was significantly higher, compared
with the abdominal obesity (−) group. The prevalence of
cardiovascular disease in non-obese (BMI < 25 kg/m2)
patients with abdominal obesity was similar to that in
obese (BMI ≥25 kg/m2) patients.
Changes in BMI after 20 years of age in type 2 diabetics
with abdominal obesity
We compared body weight at 20 years of age, at max-
imum and at admission to clarify changes in BMI in
diabetic patients with and without abdominal obesity
(Figure 2). The body weight at 20 years of age and the
maximum weight were obtained at the medical inter-
view. The mean BMI of the abdominal obesity (−) group
was < 25 kg/m2 at 20 years of age, at maximum and at
Table 1 Baseline characteristics
Abdominal obesity p
value(−) group (+) group
n 28 60
Males/Females 13/15 38/22 0.167
Age, years 55.7 ± 6.7 54.8 ± 7.3 0.575
Body mass index, kg/m2 20.9 ± 2.3 28.7 ± 4.8 <0.01
Duration of diabetes mellitus, years 11.6 ± 10.3 9.1 ± 7.8 0.216
Number of hospitalizations 1.7 ± 0.9 2.3 ± 2.0 0.176
Family history of diabetes mellitus, % 61 53 0.646
Fasting plasma glucose, mg/dL 154 ± 56 153 ± 50 0.951
Hemoglobin A1c (NGSP), % (mmol/mol) 9.3 ± 2.2 (78) 9.1 ± 1.9 (76) 0.648
Fasting insulin, IU/L 4.6 ± 2.9 9.9 ± 8.4 <0.01
Fasting C-peptide, ng/mL 1.5 ± 0.9 2.0 ± 1.0 <0.05
HOMA-IR 1.5 ± 1.0 (n = 18) 3.4 ± 3.5 (n = 30) <0.05
Maximum carotid IMT, mm 1.4 ± 0.7 1.6 ± 1.0 0.345
Diabetic retinopathy (NDR/SDR/PPDR/PDR) 16/5/0/7 41/7/3/8 0.250
Diabetic nephropathy (normo/micro/overt) 21/5/2 44/9/6 0.814
Discharge medications for diabetes mellitus
Sulfonylurea, % 32 20 0.283
Biguanide, % 7 40 <0.01
Thiazolidinedione, % 14 12 0.738
Alpha-glucosidase inhibitor, % 18 15 0.760
Glinide, % 0 5 0.548
Dipeptidyl peptidase-4 inhibitor, % 18 27 0.431
Glucagon-like peptide-1 analog, % 0 8 0.173
Insulin, % 54 38 0.248
Data are mean ± SD, number of subjects or frequency [n (%)],
NGSP national glycohemoglobin standardization program, HOMA-IR homeostasis model assessment of insulin resistance, IMT intima-media thickness,
NDR non-diabetic retinopathy, SDR simple diabetic retinopathy, PPDR preproliferative diabetic retinopathy, PDR proliferative diabetic retinopathy, normo
normoalbuminuria, micro microalbuminuria, overt overt proteinuria.
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abdominal obesity (+) group was 23.5 kg/m2 at 20 years
of age (non-obese), but reached maximum to more than
30 kg/m2 in the course. The BMI at 20 years of age was
significantly higher in the abdominal obesity (+) group
than in the abdominal obesity (−) group (23.5 kg/m2 vs
20.7 kg/m2, respectively).
Finally, we examined the relationship between WC at
admission and BMI at 20 years of age in all subjects with
type 2 diabetes (Figure 3). 52% (n = 25) in males and
43% (n = 15) in females of the type 2 diabetic patients
were not obese at 20 year-old (BMI < 25 kg/m2), but
developed abdominal obesity by the time of admission.
Discussion
The purpose of this cross-sectional study was to clarify
the clinical features of type 2 diabetic patients with
abdominal obesity. In the present study, we demonstrated
the following differences between the abdominal obesity (+)group and the abdominal obesity (−) group; 1) Hyperten-
sion and dyslipidemia were significantly more prevalent in
type 2 diabetic patients with abdominal obesity. 2) Cardio-
vascular diseases were significantly more in patients with
abdominal obesity. 3) There were no significant differences
in the prevalence of diabetic microangiopathies (diabetic
retinopathy and diabetic nephropathy) between the two
groups. 4) In the abdominal obesity (+) group, the mean
BMI was < 25 kg/m2 at 20 years of age (non-obese), but
reached maximum to more than 30 kg/m2 in the course. 5)
Substantial portion of the type 2 diabetic patients (52% in
males and 43% in females) were not obese at 20 year-old
(BMI < 25 kg/m2), but developed abdominal obesity by the
time of admission.
Abdominal obesity and atherosclerotic cardiovascular
disease
Visceral fat accumulation is accompanied by lifestyle
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Figure 1 Metabolic risk factors and cardiovascular disease in type 2 diabetic patients with abdominal obesity. (A) Prevalence of
hypertension, dyslipidemia and cardiovascular disease in type 2 diabetic patients with abdominal obesity. (B) Relationship between prevalence of
cardiovascular disease and body fat distribution. Subjects were divided according to body mass index (BMI) and waist circumference (WC).
Abdominal obesity represented WC of ≥85 cm in males and ≥90 cm in females. *P < 0.05, **P < 0.01.
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cytes in intra-abdominal visceral fat exhibit hyperlipolytic
activity, which is resistant to the antilipolytic effect of insu-
lin [28,29]. The resulting hyper-free-fatty-acidemia and
hyperglycerolemia in the portal vein increase the produc-
tion of triacylglycerol-rich lipoproteins [30-33] and
glucose in the liver [34,35], leading to dyslipidemia, insulin
resistance and diabetes. Adipose tissue is not only an
energy-storage organ, but it produces and secretes a
variety of biologically active molecules known as adi-
pocytokines, such as adiponectin, PAI-1 and TNF-α
[15,16,36,37]. Dysregulation of adipocytokines caused by
visceral fat accumulation is regarded as one of the major
pathophysiological mechanisms of atherosclerosis associ-
ated with the metabolic syndrome. Our group has demon-
strated that some of anti-diabetic, anti-hypertensive, and
anti-dyslidemic agents had potential to target obesity and
hypoadiponectinemia [38-42].In Japanese guidelines for the metabolic syndrome,
WC is used as an index of visceral fat accumulation for
practical convenience [23]. Metabolic syndrome is de-
fined as those having visceral fat accumulation expressed
by increased WC (WC ≥85 cm in males, ≥90 cm in
females) and 2 or more risk factors [23]. In the present
study, abdominal obesity was defined as WC ≥85 cm in
males and WC ≥90 cm in females. Thus, visceral fat
accumulation is suspected to be present in type 2 dia-
betic patients with abdominal obesity. Hypertension,
dyslipidemia and cardiovascular disease were signifi-
cantly more in type 2 diabetic patients with abdominal
obesity than patients without such obesity. To prevent
atherosclerotic cardiovascular disease (diabetic macro-
angiopathy), it is necessary to search thoroughly for ath-
erosclerotic cardiovascular disease in type 2 diabetes
patients with abdominal obesity. On the other hand,
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Figure 2 Changes in BMI after 20 years of age in type 2 diabetic patients. Data are mean ± SD. **P < 0.01.
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diabetic nephropathy) between the two groups, sug-
gesting that it is necessary to rule out the presence of
microangiopathy in all patients with type 2 diabetes,
regardless of abdominal obesity. Recent reports have
demonstrated that the development and progression
of diabetic microangiopathy is influenced by glycemic
control and duration of diabetes [43-46], suggesting
that it is necessary to search thoroughly for diabetic
microangiopathy in the patients with poor glycemic
control and/or long duration of diabetes.
In our study of Japanese male urban workers [12],
visceral fat accumulation (VFA ≥100 cm2) was observed in
a relatively large proportion of patients with BMI < 25 kg/





























Figure 3 Relationship between WC at admission and BMI at 20 yearsdemonstrated the presence of multiple risk factors in such
subjects [12]. From the viewpoint of abdominal obesity
(estimation of VFA from WC), we divided the participants
in the present study (type 2 diabetics) into four groups
according to BMI and presence of abdominal obesity
(Figure 1B), and demonstrated the relationship of adi-
posity with the prevalence of cardiovascular disease.
Abdominal obesity was recognized in all patients with
BMI ≥25 kg/m2, and observed in relatively large numbers
(n = 10: 26%) of non-obese patients (BMI < 25 kg/m2).
The prevalence of cardiovascular disease in such patients
with abdominal obesity (+) plus BMI < 25 kg/m2 was simi-
lar to that in obese patients (BMI ≥25 kg/m2), and signifi-
cantly higher than in patients without abdominal obesity






























of age in (A) males (B) females.
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evaluation of the risk of cardiovascular disease in type 2
diabetic patients, compared with BMI. The present study
also suggests that measurement of WC should be more
important in patients with BMI < 25 kg/m2 (non-obese)
for the prevention of clustering of multiple risk factors
and cardiovascular disease, because all patients with
BMI ≥25 kg/m2 had abdominal obesity.
Weight gain after 20 years of age in type 2 diabetic
patients with abdominal obesity
We analyzed body weight at 20 years of age and at max-
imum obtained through medical interview, and deter-
mined the changes in BMI in type 2 diabetic patients
with abdominal obesity. Interestingly, the mean BMI
was < 25 kg/m2 at 20 years of age (non-obese), but
reached maximum to more than 30 kg/m2 in the course
(Figure 2). Substantial portion of the type 2 diabetic
patients (52% in males and 43% in females) were not
obese at 20 year-old (BMI < 25 kg/m2), but developed
abdominal obesity by the time of admission (Figure 3),
suggesting that environmental factors, such as disturb-
ance of eating habits, physical inactivity and sleep disor-
ders, affected visceral fat accumulation after 20 years of
age in these patients.
Recent researches reported that subjects with abdom-
inal obesity were more likely to develop diabetes for five
years and had higher mortality within after 13 years than
those without abdominal obesity [47,48]. Considered
together, our results suggest that intervention to individ-
uals with abdominal obesity such as health education
and health guidance after health checkup should be
important in reducing the risk of future diabetes and
cardiovascular disease after 20 years of age. Our results
also showed that the mean BMI at 20 years of age was
already higher in the abdominal obesity (+) group than
in the abdominal obesity (−) group, suggesting that early
intervention such as health education and diet control
during childhood and adolescence at school and home is
important to reduce the risk of future cardiovascular
diseases.
The present study has several limitations. The study
was not prospective in design, and included a relatively
small population limited to Japanese, who have different
physique from Caucasians.
Conclusions
The present study demonstrated higher prevalence of
hypertension, dyslipidemia and cardiovascular disease
among type 2 diabetic patients with abdominal obesity
and probable visceral fat accumulation compared to
those without abdominal obesity. Furthermore, signifi-
cant weight gain was observed in type 2 diabetic patients
with abdominal obesity after 20 years of age. Theseresults suggest that education on lifestyle modification
in younger generation, to prevent visceral fat accumula-
tion is important for the prevention of type 2 diabetes
and future atherosclerotic cardiovascular disease.
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